NCT01779830 is a Phase 1 clinical trial of LY2624803 - Capsules in Transient Insomnia, sponsored by Eli Lilly and Company.

Who is sponsoring NCT01779830?

NCT01779830 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT01779830?

Interventions in NCT01779830: LY2624803 - Capsules, Zolpidem - Tablets, Placebo - Capsules, Placebo - Tablets.

What condition does NCT01779830 study?

NCT01779830 studies Transient Insomnia.

Is NCT01779830 still recruiting?

NCT01779830 is currently completed. Last updated 28 January 2013.

Last reviewed 2013-01-28 · How we verify

NCT01779830

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Crossover Study of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Subjects

Completed Phase 1 Last updated 28 January 2013

What this trial tests

Phase 1 trial testing LY2624803 - Capsules in Transient Insomnia in 32 participants. Completed in 1 November 2008.

Timeline

1 May 2008

Primary endpoint
1 November 2008

1 November 2008

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Enrollment	32
Start date	1 May 2008
Primary completion	1 November 2008
Estimated completion	1 November 2008
Sites	1 location across France

Drugs / interventions tested

LY2624803 - Capsules — full drug profile →
Zolpidem - Tablets — full drug profile →
Placebo - Capsules
Placebo - Tablets

Conditions studied

Transient Insomnia — all drugs for Transient Insomnia →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 75, any sex, with Transient Insomnia. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo
Time frame: Baseline up to Day 60

Sponsor's own description

The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy people. The study has four treatment periods. Participants will receive a single dose of LY2624803, another sleeping pill, or placebo in each treatment period. The study will last approximately 1 month for each participant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01779830 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 28 January 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01779830.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing